In vivo cancer targeting of water-soluble taxol by folic acid immobilization

Journal of Nanomedicine and Nanotechnology

Volumn 2, Issue 1, 2011, Pages

  Nakamura, Junichi ^a   Nakajima, Naoki ^a   Matsumura, Kazuaki ^a   Hyon, Suong Hyu ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 82855163429     PISSN: None     EISSN: 21577439     Source Type: Journal    
DOI: 10.4172/2157-7439.1000106     Document Type: Article

References (31)

1. Ramesh P (1998) Pharmaceutical aspects of Paclitaxel. Int J Pharm 172: 1-15.
2. Adams JD, Flora KP, Goldspiel BR, Wilson JW, Arbuck SG, et al. (1993) Taxol: a history of pharmaceutical development and current pharmaceutical concerns. J Natl Cancer Inst Monogr 15: 141-147.
3. Wang J, Mongayt D, Torchilin VP (2005) Polymeric micelles for delivery of poorly soluble drugs: preparation and anticancer activity in vitro of paclitaxel incorporated into mixed micelles based on poly(ethylene glycol)-lipid conjugate and positively charged lipids. J Drug Target 13: 73-80.
4. Rowinsky EK, McGuire WP, Guarnieri T, Fisherman JS, Christian MC, et al. (1991) Cardiac disturbances during the administration of taxol. J Clin Oncol 9: 1704-1712.
5. Chun L, Dong-Fang Y, Robert AN, Fernando C, L Clifton S, et al. (1998) Complete regression of well-established tumors using a novel water-soluble poly (L-glutamic acid)-paclitaxel conjugate. Cancer Res 58: 2404-2409.
6. William JG (2006) Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother 7: 1041-1053.
7. Xiang G, Wu J, Lu Y, Liu Z, Lee RJ (2008) Synthesis and evaluation of a novel ligand for folate-mediated targeting liposomes. Int J Pharm 356: 29-36.
8. Bae Y, Nishiyama N, Kataoka K (2007) In vivo antitumor activity ofthe folate-conjugated pH-sensitive polymeric micelle selectively releasing adriamycin in the intracellular acidic compartments. Bioconjug Chem 18: 1131-1139.
9. Seow WY, Xue JM, Yang YY (2007) Targeted and intracellular delivery of paclitaxel using multi-functional polymeric micelles. Biomaterials 28: 1730-1740.
10. Wu J, Liu Q Lee RJ (2006) A folate receptor-targeted liposomal formulation for paclitaxel: Int J Pharm 316: 148-153.
11. Lu Y, Low PS (2003) Immunotherapy of folate receptor-expressing tumors: review of recent advances and future prospects. J Control Release 91: 17-29.
12. Weitman SD, Lark RH, Coney LR, Fort DW, Frasca V (1992) Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res 52: 3396-3401.
13. Nakamura J, Nakajima N, Matsumura K, Hyon SH (2010) Water-soluble taxol conjugates with dextran and targets tumor cells by folic acid immobilization. Anticancer Res 30: 903-909.
14. Maeda H, Sawa T, Konno T (2001) Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J Control Release 74: 47-61.
15. Schwendener RA (2007) Liposomes in biology and medicine. Adv Exp Med Biol 620: 117-128.
16. Shibata H, Nakagawa S, Tsutsumi Y (2005) Optimization of protein therapies by polymer-conjugation as an effective DDS. Molecules 31: 162-180.
17. Nassimi M, Schleh C, Lauenstein HD, Hussein R, Lubbers K (2009) Low cytotoxicity of solid lipid nanoparticles in vitro and ex vivo lung models. Inhal Toxicol 21: 104-109.
18. Tsutsui Y, Tomizawa K, Nagita M, Michiue H, Nishiki T (2007) Development of bionanocapsules targeting brain tumors. J Control Release 26: 159-164.
19. Yu DH, Lu Q, Xie J, Fang C, Chen HZ (2010) Peptide-conjugated biodegradable nanoparticles as a carrier to target paclitaxel to tumor neovasculature. Biomaterials 31: 2278-2292.
20. Abu-hadid MM, Bankert RB Mayers GL (1987) Antigen-specific drug-targeting used to manipulate an immune response in vivo. Proc Natl Acad Sci USA 84: 7232-7236.
21. Matsumura Y, Maeda H (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46: 6387-6392.
22. Bisht S, Maitra A (2009) Dextran-doxorubicin chitosan nanoparticles for solid tumor therapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol 1: 415-425.
23. Chisholm EJ, Vassaux G, Martin-Duque P, Chevre R, Lambert O, et al. (2009) Cancer-specific transgene expression mediated by systemic injection of nanoparticles. Cancer Res 69: 2655-2662.
24. Adiseshaiah PP, Hall JB, McNeil SE (2010) Nanomaterial standards for efficacy and toxicity assessment. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2: 99-112.
25. Wu M, Gunning W, Ratnam M (1999) Expression of folate receptor type a in relation to cell type, malignancy, and differentiation in ovary, uterus, and cervix. Cancer Epidemiol Biomarkers Prev. 8: 775-782.
26. Shen F, Ross JF, Wang X, Ratnam M (1994) Identification of a novel folate receptor, a truncated receptor, and receptor type β in hematopoietic cells: cDNA cloning, expression, immunoreactivity, and tissue specificity. Biochemistry 33: 1209-1215.
27. Ross JF, Wang H, Behm FG, Mathew P, Wu M (1999) Folate receptor type β is a neutrophilic lineage marker and is differentially expressed in myeloid leukemia. Cancer 85: 348-357.
28. Wang H, Ross JF, Ratnam M (1998) Structure and regulation of a polymorphic gene encoding folate receptor type γ/γ′. Nucleic Acids Res 26: 2132-2142.
29. Lee RJ, Low PS. (1995) Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim Biophys Acta 1233: 134-144.
30. Zhai G, Wu J, Xiang G, Mao W, Yu B (2009) Preparation, characterization and pharmacokinetics of folate receptor-targeted liposomes for docetaxel delivery. J Nanosci Nanotechnol 9: 2155-2161
31. Chattopadhyay S, Wang Y, Zhao R, Goldman ID (2004) Lack of impact of the loss of constitutive folate receptor alpha expression, achieved by RNA Interference, on the activity of the new generation antifolate pemetrexed in HeLa cells. Clin Cancer Res 10: 7986-7993.